Skip to main content
David Rawlings, MD, Pediatric Rheumatology, Seattle, WA

DavidJRawlingsMD

Pediatric Rheumatology • Seattle, WA

Professor, Pediatrics, University of Washington School of Medicine

Join to view full profile

Dr. Rawlings is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Rawlings' full profile

Already have an account?

  • Office

    4800 Sand Point Way Ne
    Seattle, WA 98105
    Phone+1 206-987-2000

Education & Training

  • University of North Carolina at Chapel Hill School of Medicine
    University of North Carolina at Chapel Hill School of MedicineClass of 1984

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1986 - Present
  • WA State Medical License
    WA State Medical License 2001 - 2026
  • MD State Medical License
    MD State Medical License 1988 - 1991
  • American Board of Pediatrics Pediatric Rheumatology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Integrated B Cell, Toll-like, and BAFF Receptor Signals Promote Autoantibody Production by Transitional B Cells  
    David J Rawlings, Shaun W Jackson, The Journal of Immunology

Abstracts/Posters

  • Enabling Gene-Edited, Regulatory-like, T Cells (edTreg) for Treatment of IPEX and Other Autoimmune Disorders
    David J. Rawlings, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Manufacture and In Vivo Support of Gene-Edited, Regulatory-like, T-Cells (edTreg) Using a Synthetic IL2 Receptor
    David J. Rawlings, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

  • Emendo Biotherapeutics and Seattle Children’s Research Institute Announce Collaboration to Develop CRISPR-Based Therapeutic Strategy for Severe Congenital Neutropenia
    Emendo Biotherapeutics and Seattle Children’s Research Institute Announce Collaboration to Develop CRISPR-Based Therapeutic Strategy for Severe Congenital NeutropeniaDecember 22nd, 2021
  • Seattle Children’s Research Division: Celebrating 15 Years of Innovation
    Seattle Children’s Research Division: Celebrating 15 Years of InnovationNovember 12th, 2021
  • Seattle Children’s Licenses Gene-Editing Therapy to Casebia Therapeutics and Will Partner on Further Research
    Seattle Children’s Licenses Gene-Editing Therapy to Casebia Therapeutics and Will Partner on Further ResearchSeptember 27th, 2017

Dr. David Rawlings, Dr. David Rawlings, MD, Dr. D Rawlings, Dr. David J Rawlings